T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 805-809

  Bai, Jianwen ^a   Li, Xiaoyan ^b   Tong, Danian ^c   Shi, Weiwei ^d   Song, Haihan ^a   Li, Qinchuan ^a  

^a TONGJI UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Lung cancer; Polymorphism; TIM 3

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; GENOMIC DNA; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3 PROTEIN; UNCLASSIFIED DRUG; DNA; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL TIME; TIM 3 GENE; WILD TYPE; ADENOCARCINOMA; COMPARATIVE STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877140599     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0610-1     Document Type: Article

References (23)

1. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98:1120-7.
2. Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 2010;4:146-52.
3. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141-3.
4. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol. 2009;39:2492-501.
5. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536-41.
6. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245-52.
7. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102-10.
8. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093-101.
9. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763-79.
10. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction inmelanoma patients. J Exp Med. 2010;207:2175-86.
11. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187-94.
12. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137(6):978-85.
13. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012. doi: 10.1371/journal.pone.0030676.
14. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007;2:694-705.
15. Chae SC, Song JH, Pounsambath P, Yuan HY, Lee JH, Kim JJ, et al. Molecular variations in Th1-specific cell surface gene Tim-3. Exp Mol Med. 2004;36:274-8.
16. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJ, Njoku DB, et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411-5.
17. Chae SC, Park YR, Shim SC, Yoon KS, Chung HT. The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol Lett. 2004;95:91-5.
18. Chae SC, Park YR, Lee YC, Lee JH, Chung HT. The association of TIM-3 gene polymorphism with atopic disease in Korean population. Hum Immunol. 2004;65:1427-31.
19. Cao B, Zhu L, Zhu S, Li D, Zhang C, Xu C, et al. Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer. Cancer Immunol Immunother. 2010;59:1851-7.
20. Boenisch O, D'Addio F, Watanabe T, Elyaman W, Magee CN, et al. TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol. 2010;185:5806-19.
21. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, et al. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105:9331-6.
22. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127:78-88.
23. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137:978-85.